These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1142508)

  • 41. [Diethyl-stilbestrol for treatment of prostatic carcinoma].
    Cifuentes Delatte L
    Arch Esp Urol; 1990 Sep; 43(7):697-704. PubMed ID: 2125823
    [No Abstract]   [Full Text] [Related]  

  • 42. Prevention of platelet aggregation in patients with prostatic cancer during estrogen therapy.
    Koiso K; Akima H; Niijima T
    Urology; 1982 Jun; 19(6):579-83. PubMed ID: 6283703
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of stage IV carcinoma of the prostate.
    Resnick MI; Grayhack JT
    Urol Clin North Am; 1975 Feb; 2(1):141-61. PubMed ID: 1093057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progestational agents and blood coagulation. VIII. Effect of low-dose, alternate-day, estrogen-progestin combinations on blood coagulation factors in man, with a special note on the effect of freezing of blood samples.
    Ambrus JL; Courey NG; Browne BJ; Mink IB; Moore RH; Ambrus CM
    Am J Obstet Gynecol; 1977 May; 128(2):161-6. PubMed ID: 857675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of 6-[p-(4-phenylacetylpiperazin-1-yl)phenyl]-4,5-dihydro-3(2H)pyridazinone (CCI 17810) and aspirin on platelet aggregation and adhesiveness.
    Griffett EM; Kinnon SM; Kumar A; Lecker D; Smith GM; Tomich EG
    Br J Pharmacol; 1981 Apr; 72(4):697-705. PubMed ID: 7284687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer.
    Henriksson P; Stege R
    Int J Technol Assess Health Care; 1991; 7(2):220-5. PubMed ID: 1907600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of long-term estrogen replacement therapy. II. Neoplasia.
    Hammond CB; Jelovsek FR; Lee KL; Creasman WT; Parker RT
    Am J Obstet Gynecol; 1979 Mar; 133(5):537-47. PubMed ID: 220875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D
    J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of hormones on platelet intracellular calcium.
    Miller ME; Thorpe SL; Dores GM
    Thromb Res; 1995 Mar; 77(6):515-30. PubMed ID: 7624838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD; Fosså J; Aakvaag A
    J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet function tests in uraemia and under acetylsalicylic acid administration.
    Schöndoft TH; Hey D
    Haemostasis; 1974; 3(3):129-36. PubMed ID: 4461414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Acetylsalicylic acid and thrombocyte function].
    Shabalov NP; Bolotina ED
    Pediatriia; 1984 Sep; (9):29-30. PubMed ID: 6504647
    [No Abstract]   [Full Text] [Related]  

  • 56. Catechol estrogens and thrombosis: lack of a direct effect of 2-hydroxyestradiol on platelets.
    Needleman SW; Stump DC; Cohen DP
    Contraception; 1982 Feb; 25(2):185-9. PubMed ID: 6280924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
    Kaplan L
    Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
    [No Abstract]   [Full Text] [Related]  

  • 58. [The assessment of the state of the blood lipid spectrum, hemostasis, hormonal homeostasis and hemodynamics in the early diagnosis and drug correction of the cardiovascular changes in prostatic cancer patients undergoing estrogen therapy].
    Portnoĭ AS; Begunov AV
    Urol Nefrol (Mosk); 1992; (1-3):6-11. PubMed ID: 1413345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
    Varenhorst E; Alund G
    Urology; 1985 Apr; 25(4):354-6. PubMed ID: 3157256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of endocrine therapy on plasma steroids in prostatic carcinoma patients.
    Drafta D; Proca E; Schindler AE; Neacşu E; Zamfir V; Neagoe M; Teodosiu D
    Endocrinologie; 1984; 22(3):191-7. PubMed ID: 6494786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.